Frank Nocken: FDA Approves Caplacizumab Therapy for Pediatric Acquired TTP
Frank Nocken, Independent Consultant for Scientific Innovation Management, shared a post on LinkedIn:
“‘The FDA has approved Cablivi (caplacizumab) for injection to treat pediatric patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.’
‘Caplacizumab therapy is nanobody-based and built on small antibody fragments derived from heavy-chain-only antibodies, that targets von Willebrand factor, a protein that plays a central role in platelet adhesion and clot formation in aTTP.
It works by binding to the A1 domain of von Willebrand factor, blocking its interaction with platelets and helping to reduce the microvascular clots that define the disease.'”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026